In a meta-Investigation of six randomized controlled trials that enrolled hospitalized clients with COVID-19, the use of non-SARS-CoV-two-specific IVIG was not associated with a survival advantage.1 All of the included trials ended up carried out in 2020, in the event the existence of SARS-CoV-2 antibodies in blood donors was possible https://carlosc210nbp6.wikicorrespondent.com/user